Experimental agent blocks prostate cancer in animal study

An experimental drug has blocked the progression of prostate cancer in an animal model with an aggressive form of the disease, new research shows. The agent, OSU-HDAC42, belongs to a new class of drugs called histone deacetylase (HDAC) inhibitors, compounds designed to reactivate genes that normally protect against cancer but are turned off by the cancer process.

Read the whole article on Physorg

More from Physorg